Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immune system may guide chemotherapy for breast cancer

04.04.2011
A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

Researchers at the University of California, San Francisco, demonstrated that the level of macrophages and CD8+ T-cells, two key components of the human immune system, can help predict recurrence and overall survival. New biologic-targeted therapies impairing macrophage recruitment into tumors show promising results in preclinical studies.

"Phase I clinical trials are blunt instruments because their goal is often limited to determining a safe dose for a new drug," said Lisa Coussens, Ph.D., professor in the department of pathology at the University of California, San Francisco. "Using preclinical transgenic mouse models of cancer development, scientists cannot only help determine a safe dose for a new drug, but also identify biomarkers indicative of the biological response of the new drug. Identification of relevant biomarkers can then be translated to clinical studies and help to determine which patients are or are not responding to the drug."

For the current study, Coussens and colleagues tested the effect of PLX3397, a compound currently in a Phase I clinical trial and developed by Plexxikon Inc., which inhibits colony stimulating factor 1 receptor kinase activity, and thereby blocks macrophage recruitment into tumors.

Blocking macrophage recruitment, in combination with paclitaxel, slowed primary tumor development and reduced metastasis in the laboratory animals that were studied. Moreover, these measureable improvements were accompanied by a decreased tumor vessel density and the increased presence of immune cells with anti-tumor properties in the tumors of these mice.

"Understanding more about this tumor microenvironment response can help enhance the effectiveness of chemotherapy," said Coussens.

Coussens and colleagues are working with Plexxikon to further test PLX3397 in other cancers, including mesothelioma, where blocking macrophage recruitment also shows promise.

Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration

Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.

Jeremy Moore | EurekAlert!
Further information:
http://www.aacr.org

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>